Industrial-scale manufacturing of Cinryze (C1-esterase inhibitor, human) will stay on schedule despite an FDA complete response letter requesting additional information about the expansion, according to ViroPharma Inc.'s President and CEO Vincent Milano. (BioWorld Today)